BioCryst Pharmaceuticals 배당 및 자사주 매입
배당 기준 점검 0/6
BioCryst Pharmaceuticals 배당금을 지급한 기록이 없습니다.
핵심 정보
n/a
배당 수익률
-0.8%
자사주 매입 수익률
| 총 주주 수익률 | -0.8% |
| 미래 배당 수익률 | 0% |
| 배당 성장률 | n/a |
| 다음 배당 지급일 | n/a |
| 배당락일 | n/a |
| 주당 배당금 | n/a |
| 배당 성향 | n/a |
최근 배당 및 자사주 매입 업데이트
업데이트 없음
Recent updates
내러티브 업데이트 • May 16
BCRX: Astria Integration And Licensing Deal Will Support Hereditary Angioedema Expansion
Analysts have nudged their average price target on BioCryst higher by low single digits in recent weeks, citing reiterated long-term revenue goals following the Astria Therapeutics acquisition, ongoing confidence in Orladeyo and navenibart sales potential, and steadier expectations for future profitability and P/E levels. Analyst Commentary Recent research has leaned constructive on BioCryst, with several bullish analysts adjusting their price targets upward and reaffirming confidence in the company’s long term revenue framework following the Astria Therapeutics acquisition.
내러티브 업데이트 • May 01
BCRX: Astria Deal And FY26 Goals Will Support Rare Disease Upside
Analysts have inched their average price target on BioCryst Pharmaceuticals higher by $0.10 to $21.40, reflecting research that points to steady commercial execution, reiterated long term revenue goals following the Astria Therapeutics acquisition, and continued interest in the BCX17725 program as well as Orladeyo and navenibart sales potential. Analyst Commentary Recent research highlights a mix of enthusiasm and caution around BioCryst, with price targets edging higher and coverage resuming as analysts digest the Astria Therapeutics acquisition, updated guidance, and the company’s rare disease portfolio.내러티브 업데이트 • Apr 17
BCRX: Astria Integration And 2031 Debt Structure Will Support Hereditary Angioedema Expansion
Narrative Update Analysts have nudged their price targets on BioCryst Pharmaceuticals higher by $1. This reflects continued confidence in management's reiterated FY26 guidance, the integration of the Astria Therapeutics acquisition, and the longer term potential they see in Orladeyo and navenibart.내러티브 업데이트 • Apr 03
BCRX: Astria Acquisition And FY26 Guidance Will Support Long-Term Revenue Potential
Analysts lifted their price target on BioCryst Pharmaceuticals to $22 from $21, citing steady forward guidance, reaffirmed peak revenue goals following the Astria Therapeutics acquisition, and confidence in Orladeyo and the BCX17725 program as key factors supporting the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as supported by reiterated FY26 guidance and peak revenue goals, which they view as evidence that management is confident in the current growth plan.
내러티브 업데이트 • Mar 20
BCRX: Astria Acquisition And FY26 Outlook Will Support Long Term Upside
Analysts lifted their price targets on BioCryst to a range of $17 to $22, citing steady FY26 guidance, reaffirmed peak revenue goals, and confidence in the Astria Therapeutics acquisition and BCX17725 data timeline as key supports for the higher valuations. Analyst Commentary Recent Street research on BioCryst highlights a mix of optimism around the Astria Therapeutics acquisition, reaffirmed FY26 guidance, and the commercial trajectory of Orladeyo, alongside growing interest in the BCX17725 program as a potential long term driver.Seeking Alpha • Mar 17
BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real
Summary BioCryst Pharmaceuticals remains a cash-generative orphan drug player, with ORLADEYO as its mature but still growing lead asset. Despite recent buyout rumors, I view a takeout as speculative and maintain a 'Hold' rating until more definitive catalysts emerge. ORLADEYO's future growth is challenged by new high-efficacy HAE treatments, while navenibart's Phase 3 data (expected 2027) could redefine BCRX's outlook. Financially, BCRX preserved liquidity post-Astria acquisition, guiding FY26 revenues of $625M–$645M and outpacing non-GAAP opex. Read the full article on Seeking Alpha내러티브 업데이트 • Mar 05
BCRX: Astria Acquisition And FY26 Outlook Will Support Long-Term HAE Leadership
Analysts have raised their blended price target on BioCryst Pharmaceuticals to about $21.30 from $20.50, citing reaffirmed FY26 guidance, reiterated peak revenue goals after the Astria Therapeutics acquisition, and continued confidence in the commercial ramp and the BCX17725 data timeline. Analyst Commentary Bullish Takeaways Bullish analysts see the higher blended price targets, up to about $22, as reflecting confidence in execution on the FY26 guidance and the longer term revenue framework.내러티브 업데이트 • Feb 19
BCRX: Astria Acquisition Will Drive Hereditary Angioedema Franchise Expansion
Analysts have reaffirmed their $32.00 fair value estimate for BioCryst Pharmaceuticals and supported a $17.00 price target, citing expectations for Orladeyo to potentially reach $900m in sales by 2029 and for navenibart to approach $1b in risk adjusted sales following the Astria Therapeutics acquisition. Analyst Commentary Bullish analysts view the reaffirmed US$32.00 fair value estimate and the US$17.00 price target as grounded in a clearer revenue roadmap, with both Orladeyo and navenibart framed as key building blocks of the story rather than optional upside.내러티브 업데이트 • Feb 05
BCRX: Pediatric Approval And 2031 Financing Will Strengthen Long Term Outlook
Narrative Update Overview Analysts have raised their price target on BioCryst Pharmaceuticals from US$11.00 to US$13.00, reflecting updated assumptions on revenue, profit margins, discount rate and future P/E multiples in their valuation work. What's in the News Entered a new loan agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. for term loans with gross proceeds of US$400 million, issued in multiple tranches and maturing on January 23, 2031, with quarterly interest-only payments and principal due at maturity (company announcement).내러티브 업데이트 • Jan 22
BCRX: Pediatric Expansion And 2025 Profitability Outlook Will Support Long-Term HAE Leadership
Narrative Update Overview Analysts now see fair value for BioCryst Pharmaceuticals at US$20.50 per share, a US$0.10 adjustment that reflects updated assumptions on revenue growth, profit margins, discount rate, and future P/E levels. What's in the News BioCryst issued full year 2026 earnings guidance, with total revenue expected in a range of US$635 million to US$660 million (company guidance).내러티브 업데이트 • Jan 08
BCRX: Astria Acquisition Will Extend HAE Leadership With Long Acting Injectable Through 2042
Narrative Update: BioCryst Pharmaceuticals The updated analyst price target for BioCryst Pharmaceuticals has moved modestly higher to about $20.60 from $20.40, with analysts pointing to the planned $700m acquisition of Astria Therapeutics, expected SG&A synergies, and the potential of HAE candidate navenibart to support BioCryst's hereditary angioedema franchise as key reasons for their revised view. Analyst Commentary Street research around BioCryst's planned US$700m acquisition of Astria Therapeutics clusters around the same core themes, but with different levels of enthusiasm about execution risk, competitive pressure, and valuation.내러티브 업데이트 • Dec 24
BCRX: Astria Acquisition Will Extend Hereditary Angioedema Leadership Through Navenibart
We raise our BioCryst Pharmaceuticals fair value estimate to $32.00 from $28.15, as analysts highlight the accretive $700M Astria Therapeutics acquisition and its potential to extend the company’s hereditary angioedema leadership with long acting navenibart through the next decade. Analyst Commentary Analysts with a positive view on the stock are broadly endorsing BioCryst's acquisition of Astria Therapeutics, describing it as a value-accretive move that enhances the company’s hereditary angioedema portfolio and extends its potential growth runway into the 2030s and beyond.내러티브 업데이트 • Dec 10
BCRX: Astria Acquisition Will Extend HAE Leadership With Long-Acting Injectable Through 2042
Analysts have lifted their average price targets on BioCryst Pharmaceuticals by a mid-teens dollar amount into the mid to high $20s per share range, citing the proposed $700M acquisition of Astria Therapeutics as a strategically sound, earnings-accretive move that extends the company’s hereditary angioedema leadership and reduces long-term growth risk. Analyst Commentary Street research following the Astria Therapeutics deal skews constructive, with most price target revisions reflecting higher confidence in BioCryst’s long term growth profile and durability in hereditary angioedema, even as investors weigh near term dilution and competitive risks.내러티브 업데이트 • Nov 26
BCRX: Acquisition Will Extend HAE Franchise With New Long-Acting Candidate Through 2042
BioCryst Pharmaceuticals’ fair value estimate has increased from $19.73 to $20.40 per share. Analysts cite the company’s acquisition of Astria Therapeutics and improved long-term growth prospects following recent price target raises by multiple firms.내러티브 업데이트 • Nov 12
BCRX: Acquisition Will Drive Earnings Upside With New HAE Candidate Through 2042
BioCryst Pharmaceuticals' fair value estimate has been adjusted downward by approximately $0.55 per share, as analysts incorporate the strategic rationale and expected synergies following the announced acquisition of Astria Therapeutics. Analyst Commentary Market observers have provided a range of insights following BioCryst Pharmaceuticals' acquisition of Astria Therapeutics.분석 기사 • Nov 06
Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Last week saw the newest third-quarter earnings release from BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ), an...내러티브 업데이트 • Oct 29
Acquisition Of Leading HAE Therapy Candidate Will Drive Future Market Expansion
Analysts have raised their price target for BioCryst Pharmaceuticals from $18.50 to approximately $20.27 per share. This change reflects optimism about the company's acquisition of Astria Therapeutics and its anticipated impact on future growth and market position.내러티브 업데이트 • Oct 14
Expanding Rare Disease Pipeline Will Open New Markets
Analysts have raised their fair value estimate for BioCryst Pharmaceuticals to $18.50 from $16.73. They cited the anticipated long-term benefits and strategic alignment from the recent Astria Therapeutics acquisition, despite some near-term uncertainties.분석 기사 • Aug 07
BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
A week ago, BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) came out with a strong set of quarterly numbers that could...새로운 내러티브 • May 09
ORLADEYO Pipeline Will Deliver New Therapeutic Opportunities
ORLADEYO's revenue growth, patient conversion, and reduced royalty payments enhance profitability, cash flow, and financial stability for BioCryst Pharmaceuticals.Seeking Alpha • Feb 25
BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical
Summary I initially rated BioCryst a "Sell" in November 2023, but am now upgrading to "Hold" as the company has outperformed my expectations, despite competitive pressures. Orladeyo, BioCryst's main revenue source, saw impressive growth in 2024, but faces significant competition and may not reach management's $1bn annual revenue target in my view. Q4 2024 earnings showed a notable improvement with a reduced GAAP operating loss and a positive non-GAAP operating profit, but guidance for ~22% growth led to a sell-off. Despite promising near-term growth and potential label expansions, long-term risks and reliance on Orladeyo remain concerns, making the stock fairly valued at this time in my view. Read the full article on Seeking Alpha분석 기사 • Feb 15
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Fly 25% But Investors Aren't Buying For Growth
The BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) share price has done very well over the last month, posting an...Seeking Alpha • Dec 09
BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy
Summary BioCryst remains a "Buy" due to ORLADEYO's proven success, potential growth, and management's confidence despite significant competition and a one-dimensional revenue stream. Q3 2024 showed mixed results with a modest revenue beat and slight earnings miss, leading to a 13% stock drop on higher volume. ORLADEYO's revenue guidance is strong, with expectations of reaching $1 billion annually by 2029, driven by its convenience and efficacy. BioCryst's financial health is solid with positive cash flow in Q3, a strong cash position, and no immediate need for additional capital. Read the full article on Seeking AlphaSeeking Alpha • Sep 29
BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)
Summary BioCryst's Q2 earnings exceeded expectations, with Orladeyo revenues driving a 34% YoY growth, signaling a faster path to profitability. Despite fierce competition, Orladeyo's market performance and international expansion bolster confidence in its potential to reach $1 billion in annual revenue. BioCryst's financial health is solid, with a current ratio above 2 and a cash runway of approximately 2.5 years, aiming for positive cash flow by late 2025. Upgrading BioCryst to a "hold" rating due to improved financials and Orladeyo's growth, but caution remains due to competition and potential R&D setbacks. Read the full article on Seeking Alpha지급의 안정성과 성장
배당 데이터 가져오는 중
안정적인 배당: 과거에 BCRX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.
배당금 증가: BCRX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.
배당 수익률 vs 시장
| BioCryst Pharmaceuticals 배당 수익률 vs 시장 |
|---|
| 구분 | 배당 수익률 |
|---|---|
| 회사 (BCRX) | n/a |
| 시장 하위 25% (US) | 1.4% |
| 시장 상위 25% (US) | 4.3% |
| 업계 평균 (Biotechs) | 2.4% |
| 분석가 예측 (BCRX) (최대 3년) | 0% |
주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 BCRX 의 배당 수익률을 평가할 수 없습니다.
고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 BCRX 의 배당 수익률을 평가할 수 없습니다.
주주 대상 이익 배당
수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 BCRX 의 지급 비율을 계산하기에는 데이터가 부족합니다.
주주 현금 배당
현금 흐름 범위: BCRX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.
높은 배당을 제공하는 우량 기업 찾기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 03:45 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
BioCryst Pharmaceuticals, Inc.는 27명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Steven Seedhouse | Cantor Fitzgerald & Co. |